Why 'Expensive' Ethereum Will Dominate Institutional DeFi
The metrics that matter for institutional adoption are entirely different to retail. While retail users flee Ethereum's transaction fees for cheaper chains, institutions will gladly pay that premium for security when moving hundreds of millions. The premium that people are willing to pay for a safe infrastructure is not an issue. Ethereum's 'weaknesses' are actually its institutional moat.
A tale of two markets
Examining the numbers, the difference in perspective between retail and institutional investors makes sense. If you are buying a memecoin for $50, you don't want to pay $10 in transaction fees. But when it comes to settling a $500 million interest rate swap, shelling out $10 to ensure a secure transaction is a small price for that peace of mind.
One needs to look no further than TradFi to see this perspective is not new, and the security premium to transact on Ethereum is actually the product. There's a reason why institutions pay more to trade on the NYSE than the Pink Sheets (securities on OTC exchanges), and why they continue to transact through SWIFT, despite its costs. It's all about legitimacy and a proven track record of conducting transactions in a secure and compliant manner. The same will apply to blockchains.
The idea of having hundreds of millions of dollars in funds stuck on an inoperable network is the definition of a nightmare for institutions. Many institutions value the battle-tested security of chains like Ethereum rather than ones that focus on speed. If you take one thing away from this op-ed, understand that traditional finance always pays for infrastructure reliability.
Preparing for regulations
What investors need most is a robust, market tested base-layer blockchain that is widely accepted among financial institutions as a neutral settlement layer. Ethereum gets serious institutional engagement because the network is properly integrated with existing infrastructure. It's what it was built for.
One proof point is the number of major banks building on Ethereum, who get regulatory comfort with Ethereum's decentralization, as well as from the pool of developer talent that has been, and will continue to be, concentrated within the Ethereum ecosystem. This just might be a self-reinforcing cycle of institutional adoption.
A feature, not a failure
We need to stop seeing Ethereum's high fees as a failure – they're a feature that naturally segments the market. Some chains are intentionally optimized for low cost, fast, micro transactions. Institutions need, and will pay for, the digital equivalent of Fort Knox for large ones, where liquidity is available.
Instead of looking at metrics like daily active users or translation counts, institutions are taking a more fundamental approach. They are watching where regulated entities are building their infrastructure, and are focused on the big game of institutional settlement.
So the next time someone declares Ethereum dead, ask them where they would rather settle a $500 million transaction? The answer reveals why reports of Ethereum's demise are greatly exaggerated – and why institutions betting on 'boring' Ethereum infrastructure will capture the real value in DeFi's institutional future.Sign in to access your portfolio

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
RBC Capital Sees Strong Growth Potential for Abbott Laboratories (ABT)
Abbott Laboratories (NYSE:ABT) ranks among the . RBC Capital maintained its Outperform rating on Abbott Laboratories (NYSE:ABT) on July 15 and raised its price target from $145 to $147. The firm pointed to Abbott's strong single-digit revenue and double-digit EPS growth potential as examples of its ability to provide top-tier financial growth in the medical technology industry. According to RBC Capital's intra-quarter checks, Abbott Laboratories (NYSE:ABT) maintains positive healthcare utilization in Q2. Moreover, Abbott's diabetes brand, which has been attracting a lot of investor interest, was one of the several growth catalysts mentioned in the firm's report. The less elective nature of Abbott's medical device portfolio was also mentioned by RBC as a benefit. RBC Capital's sustained belief in Abbott Laboratories (NYSE:ABT) as the best-performing large cap in its coverage year-to-date is bolstered by other positives such as business momentum in diabetes care, favorable trends in diagnostics, stability in nutrition, and strength in established pharmaceuticals. Abbott Laboratories (NYSE:ABT) is a leading global healthcare company that manufactures a wide range of branded generic medications, medical devices, diagnostics, and nutritional items. While we acknowledge the potential of ABT as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. Read More: and Disclosure: None. Sign in to access your portfolio
Yahoo
an hour ago
- Yahoo
Johnson & Johnson (JNJ) Adjusts Revenue and EPS Outlook; Stifel Hikes Price Target
Johnson & Johnson (NYSE:JNJ) ranks among the . On July 16, Stifel maintained its Hold rating on Johnson & Johnson (NYSE:JNJ), but increased its price target for the healthcare giant from $155 to $165. The price target increase comes after JNJ revised its outlook, which now predicts adjusted operational revenue growth of roughly 3.5% instead of the 2.5% midpoint estimate that was previously projected. Pixabay/Public Domain Johnson & Johnson (NYSE:JNJ) also raised its outlook for full-year earnings per share from $10.50 to $10.70 to a range of $10.80 to $10.90. The company cited stronger top-line performance, currency effects, and a lower anticipated impact from tariffs for this improvement. From its initial estimate of $400 million, the healthcare company now projects a $200 million tariff impact in 2025. Johnson & Johnson (NYSE:JNJ) is a notable name in the healthcare industry, which includes sub-sectors like pharmaceuticals, medical equipment, and consumer health products. The company is known for creating medications to treat a variety of conditions and diseases, including cancer, diabetes, and HIV/AIDS. While we acknowledge the potential of JNJ as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. Read More: and Disclosure: None.
Yahoo
an hour ago
- Yahoo
VAALCO Schedules Second Quarter 2025 Earnings Release and Conference Call
HOUSTON, July 28, 2025 (GLOBE NEWSWIRE) -- VAALCO Energy, Inc. (NYSE: EGY; LSE: EGY) ('Vaalco' or the 'Company') today announced the timing of its second quarter 2025 earnings release and conference call. The Company will issue its second quarter 2025 earnings release on Thursday, August 7, 2025 after the close of trading on the New York Stock Exchange and host a conference call to discuss its financial and operational results on Friday morning, August 8, 2025 at 9:00 a.m. Central Time (10:00 a.m. Eastern Time and 3:00 p.m. London Time.) Interested parties in the United States may participate toll-free by dialing (833) 685-0907. Interested parties in the United Kingdom may participate toll-free by dialing 08082389064. Other international parties may dial (412) 317-5741. Participants should ask to be joined to the 'Vaalco Energy Earnings Conference Call.' This call will also be webcast on VAALCO's website at An audio replay will be available on the Company's website following the call. About Vaalco Vaalco, founded in 1985 and incorporated under the laws of Delaware, is a Houston, Texas, USA based, independent energy company with a diverse portfolio of production, development and exploration assets across Gabon, Egypt, Côte d'Ivoire, Equatorial Guinea, Nigeria and Canada. For Further Information Vaalco Energy, Inc. (General and Investor Enquiries) +00 1 713 543 3422 Website: Al Petrie Advisors (US Investor Relations) +00 1 713 543 3422 Al Petrie / Chris Delange Buchanan (UK Financial PR) +44 (0) 207 466 5000 Ben Romney / Barry Archer Vaalco@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data